Revelation Biosciences, Inc. (REVB)
After hours:
- Business Wire
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
SAN DIEGO, September 24, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive topline data fr
- Business Wire
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
SAN DIEGO, August 21, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,548,060 shares of common stock, issued by the Company on February 5, 2024 (the "Existing Warrants"), at the reduced ex
